Avanir Pharmaceuticals Inc

Avanir Pharmaceuticals — Investor Day (October 2013)

79 slides from Avanir Pharmaceuticals's investor day presentation, Oct 29, 2013

  1. Slide 1: Building a Leading CNS Biopharma

    Building a Leading CNS Biopharma Investor Relations Day October 2013 NASDAQ: AVNR

  2. Slide 2: Welcome

    Welcome Ian Clements, PhD Senior Director, IR & Corporate Communications

  3. Slide 3: Forward-looking Statement

    Forward-looking Statement Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir’s plans, potential opportunities, financial or other expectations, projections, goals, objectives, milestones, strategies, market growt

  4. Slide 4: Agenda

    Agenda Registration/Lunch Welcome Ian Clements, PhD Vision Keith Katkin Robust PBA Franchise Rohan Palekar NUEDEXTA & PBA Clinical Experience Gus Alva, MD The Rich Pharmacology of DM Joao Siffert, MD DM Potential Future Indications Joao Siffert, MD/Rohan Palekar AVP-825: A Potential New Migraine The

  5. Slide 5: The Vision

    The Vision Keith Katkin CEO & President

  6. Slide 6: Avanir: A Leading Specialty BioPharma

    Avanir: A Leading Specialty BioPharma NUEDEXTA® in Pseudobulbar Affect (PBA) Large market with a high unmet medical need n First and only FDA & EMA approved therapy for PBA Robust and growing revenues Broad Development Pipeline Across Three Assets Pain: MS pain, DPN pain, migraine, many others Mood/

  7. Slide 7: 2013: A Break-Out Year for Avanir

    2013: A Break-Out Year for Avanir REGULATORY: CLINICAL: 1. AVP-786 FDA Fast Path 1. MS Pain 2. NUEDEXTA EU Approval 2. AD Agitation 3. PD Dyskinesia 4. PBA Registry PRISM 2 Estimates for fiscal year ending Sep 30, 2013; Cash used excludes $20m Optinose payment 7

  8. Slide 8: A Promising Future

    A Promising Future GROWING REVENUES (Gross run-rate ~ $110 million) 1 APPROVED PRODUCT +1 Potential New Approved Product (CY2014) (potential in the $100s of millions) STUDIES IN 4 POTENTIAL NEW INDICATIONS (potential in the $ billions) LONGEVITY OF FRANCHISE (exclusivity to 2030+ with AVP-786) 8

  9. Slide 9: Growing NUEDEXTA Franchise

    Growing NUEDEXTA® Franchise 30 20 10 0 FY11 FY12 FY13 Numbers for fiscal year ending Sep 30, 2013 are approximate; FY12 vs. FY13 growth approximate 9

  10. Slide 10: Dextromethorphan—Rich Pharmacology

    Dextromethorphan—Rich Pharmacology Dextromethorphan provides a unique multimodal pharmacological approach that combines key features of approved therapies for: Mood Disorders / Depression Neuropathic Pain AD/Dementia Movement Disorders Other Behavior / Neuropsychiatric Disorders Page10

  11. Slide 11: Business Development Strategy

    Business Development Strategy 2012 2013 TRANSACTION TRANSACTIONS FUTURE “LIFECYCLE” “COMMERCIAL” TRANSACTIONS License for License for NDA- n Leverage next-generation ready migraine drug commercial ü DM compounds ü (AVP-825) infrastructure (AVP-786) n Expand pipeline Co-promote of Januvia diabetes ü

  12. Slide 12: Broad Pipeline—Today

    Broad Pipeline—Today PRE-CLIN PHASE 1 PHASE 2 PHASE 3 FILED MARKET AVANIR PROGRAMS AVP-923 Pseudobulbar Affect Neuropathic Pain (MS) Data Q4CY13 Agitation (Alzheimer’s) Data H2CY14 Dyskinesia (Parkinson’s) Data H2CY14 AVP-786 Various Indications AVP-825 Migraine NDA filing Q1CY14 INVESTIGATOR PROGRA

  13. Slide 13: Strong Patent Estate

    Strong Patent Estate Last to Expire (U.S. / Europe) • 3 in U.S. NUEDEXTA • 1 in Europe 2026 / 2023 • 1 in U.S. AVP-786 • 1 in Europe 2030 / 2028 AVP-825 • 4 in U.S. 2023

  14. Slide 14: Today's Speakers

    Today’s Speakers Rohan Palekar Chief Commercial Officer, Avanir Pharmaceuticals Market Opportunities Joao Siffert, M.D.—Neurologist Chief Scientific Officer, Avanir Pharmaceuticals Pipeline Programs Gus Alva, M.D.—Geriatric Psychiatrist Medical Director, ATP Clinical Research (Orange County, CA) Ger

  15. Slide 15: Robust PBA Franchise

    Robust PBA Franchise Rohan Palekar Chief Commercial Officer

  16. Slide 16: Significant Opportunity with the PBA Franchise

    Significant Opportunity with the PBA Franchise Strong Foundation Large Unmet Opportunity Highly Efficacious & Safe Product 16

  17. Slide 17: Growing NUEDEXTA Franchise

    Growing NUEDEXTA® Franchise [Graphic Appears Here] 1,000,000 750,000 500,000 250,000 0 Jan-11 Apr-11 Jul-11 Oct-11 Jan-12 Apr-12 Jul-12 Nov-12 Feb-13 May-13 Aug-13 Nov-13 Feb-14 May-14 Aug-14 Dec-14 Source: IMS Health Monthly NPA (National Prescription Audit) 17

  18. Slide 18: PBA is a Prevalent Disorder: PRISM Registry

    PBA is a Prevalent Disorder: PRISM Registry [Graphic Appears Here] 5000+ Compelling sample size in Results community setting with consistent with patients with brain past data disease/injury http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072232 18

  19. Slide 19: PBA: A Large Market with a High Unmet Need

    PBA: A Large Market with a High Unmet Need [Graphic Appears Here] Patients with key neurological disorders: 18 million Patients with moderate-severe PBA (9.3%)*: ~1.8 million ~4.8k ~48k ~55k ~470k ~396k ~820k 12% 12% 5.5% 9.4% 6.6% 16.4% Based on PRISM Registry data; Brooks et al. PLOS One, August 2

  20. Slide 20: Large Unmet Opportunity Remains in PBA

    Large Unmet Opportunity Remains in PBA PBA Prevalent populations:* [Graphic Appears Here] * Patients with moderate-to-severe PBA, approximate 20

  21. Slide 21: NUEDEXTA Impact on PBA Patient

    NUEDEXTA Impact on PBA Patient 21

  22. Slide 22: Continuing to Grow the PBA Opportunity

    Continuing to Grow the PBA Opportunity… Strategy Key Tactics PBA Awareness & Diagnosis • 152 Sales Representatives—80 Institutional—72 Retail • PBA Education & Screening Physician Adoption • NUEDEXTA Clinical Sell Patient Access • Contracting (75% Lives Covered) • Patient Assistance Programs • PBA D

  23. Slide 23: PRISM II: Real World Treatment of PBA with NUEDEXTA

    PRISM II: Real World Treatment of PBA with NUEDEXTA Patient Population Patients with Stroke, Dementia and TBI with PBA in community setting Study Endpoints Impact on PBA episodes: Episode Count and CNS-LS* scale Quality of Life: Visual Analog Scale Overall Medication Impact: Clinician and Patient Gl

  24. Slide 24: Experience with NUEDEXTA for PBA

    Gus Alva, MD Experience with NUEDEXTA for PBA

  25. Slide 25: The Rich Pharmacology of Dextromethorphan

    The Rich Pharmacology of Dextromethorphan Joao Siffert, MD Chief Scientific Officer

  26. Slide 26: DM Binds to Key Receptors in the CNS

    DM Binds to Key Receptors in the CNS NMDA Serotonin Receptor Reuptake Antagonist Inhibitor Sigma-1 Norepinephrine Receptor Reuptake Agonist Inhibitor (Ki = 200 nM)3-5 nM for inhibition of uptake; 13 µM for inhibition of binding)6-9 1. Netzer R, et al. Eur J Pharmacol. 1993;238(2-3):209-16; 2. Jaffe

  27. Slide 27: Potential Therapeutic Applications of DM Pharmacology

    Potential Therapeutic Applications of DM Pharmacology NMDA Serotonin Sigma-1 Norepinephrine Receptor Reuptake Receptor Reuptake Antagonist Inhibitor Agonist Inhibitor Alzheimer’s Depression Depression Depression Cognition Anxiety Anxiety Cognition Parkinson’s PTSD Pain Movement Disorder Depression I

  28. Slide 28: Dextromethorphan (DM)

    Dextromethorphan (DM) Non-opiate, semi-synthetic derivative of morphinan compou Identified in the 1950’s while lo for a non-addictive substitute f codeine Approved as prescription antitus drug in 1954 Changed to OTC in 1958 Limitation: rapidly metabolized CYP2D6 to dextrorphan (DX) [Graphic Appears

  29. Slide 29: Overcoming the DM Limitation

    Overcoming the DM Limitation… NUEDEXTA Approved in US (2010) and EU (2013) PHARMACOKINETICS OF DM 600 h/ml) 500 400 of DM (ng * 300 AUC 200 100 0 [Graphic Appears Here] AUC: area under the curve. 1. Steinberg GK, et al. J Neurosurg. 1996;84(5):860-866; 2. NUEDEXTA® (dextromethorphan HBr and quinidin

  30. Slide 30: Next Generation Pipeline Asset: Deuterated Dextromethorphan

    Next Generation Pipeline Asset Deuterated Dextromethorphan

  31. Slide 31: Deuterated DM (AVP-786) in Development

    Deuterated DM (AVP-786) in Development Metabolically labile hydrogen atoms (methoxy and N-methyl) replaced with deuterium Intrinsic pharmacology and toxicology remain unchanged, but The molecule is metabolized at a reduced rate Potential advantages Pharmacological similarities with DM allow a faster

  32. Slide 32: Pharmacokinetic Profile of AVP-786

    Pharmacokinetic Profile of AVP-786 AVP-786 Requires Significantly Less Quinidine to Achieve Plasma Concentrations Comparable to DM in Humans 32

  33. Slide 33: Potential Future Indications: Commercial Opportunities & Scientific Rationale

    DM Potential Future Indications: Commercial Opportunities & Scientific Rationale Joao Siffert, MD—Chief Scientific Officer Rohan Palekar—Chief Commercial Officer

  34. Slide 34: Broad & Deep Future Potential Indications

    Broad & Deep Future Potential Indications Pain Refractory DPNP, Pain Behavioral Disruption/ PBA, Agitation in AD Emotional Liability Mood Disorders Treatment Resistant MDD Movement Disorders/Other PD-LID, Cognition 34

  35. Slide 35: Neuropathic Pain: The Potential Commercial Opportunity

    Neuropathic Pain The Potential Commercial Opportunity 35

  36. Slide 36: Opportunity in Pain Management

    Opportunity in Pain Management Dextromethorphan may offer a benefit in many pain states Cancer Pain Central Pain in MS Chemo-induced Neuro Pain Refractory Diabetic Peripheral Fibromyalgia Low Back Pain Neuropathic Pain (DPNP) Post-Herpetic Pain Post-operative neuropathic pain HIV Pain Significant un

  37. Slide 37: Another Option for Refractory Diabetic Peripheral Neuropathic Pain

    Another Option for Refractory Diabetic Peripheral Neuropathic Pain (DPNP) [Graphic Appears Here] High prevalence disorder Current therapies have challenges High # of inadequate/partial responders Safety and dosing limitations High morbidity Therapies with new MOAs Therapies that offer benefits over

  38. Slide 38: DM Has Potential to Offer Unique Solution for Patients

    DM Has Potential to Offer Unique Solution for Patients DM Offers a Compelling Proposition… Need for n Unique Pharmacological Profile New Pain—Impacts Multiple Receptors Medication n Clinical Profile—Promising Efficacy—Potential Safety/Tolerability Benefit—Dosing Preference n Differentiated Pain medi

  39. Slide 39: DPNP Commercial Opportunity (U.S.)

    DPNP Commercial Opportunity (U.S.) [Graphic Appears Here] Sources: CDC-Diabetes Fact Sheet, IDF Diabetes Atlas; Veves, Pain Med. 2008;9(6):660-74; Daousi et al., Diabetes Med. 2004 Sep; 21(9); Bril et al., Neurology 2011;76:1-1; Freynhagen et al., Pain, 2005;115;254-263; Diabetes Care, July 2008;31(

  40. Slide 40: Neuropathic Pain Scientific Rationale

    Neuropathic Pain Scientific Rationale

  41. Slide 41: Neuropathic Pain Rationale—Pharmacology

    Neuropathic Pain Rationale—Pharmacology NMDA Serotonin Receptor Reuptake Antagonist Inhibitor Sigma-1 repinephrine Receptor Reuptake Agonist Inhibitor [Graphic Appears Here] 41

  42. Slide 42: Neuropathic Pain Rationale: Controlled Clinical Data

    Neuropathic Pain Rationale: Controlled Clinical Data Clinical Studies with DM Four Avanir-sponsored potential efficacy of AVP-923 in pain studies demonstrated DPN Pain studies (PII & PIII) showed statistically significant Two studies in PBA efficacy of DM/Q in patients showed relieving pain, statist

  43. Slide 43: AVP-923 Efficacy in Phase III DPN Pain

    AVP-923 Efficacy in Phase III DPN Pain (N=379) Consistent Efficacy across the primary and secondary endpoints SCALE DESCRIPTION 45/30 VS. PBO 30/30 VS. PBO Pain Rating Scale (primary endpoint) Rate pain over past 12 hours p < 0.0001 p < 0.0001 Present Pain Intensity Scale Describes patient’s present

  44. Slide 44: AVR-130 (PRIME): Phase II Trial in MS Central Neuropathic Pain

    Study AVR-130 (PRIME): Phase II Trial of AVP-923 Central Neuropathic Pain in Multiple Sclerosis n Primary Endpoint—DM PK vs. Pain Relief n Secondary Endpoints—Fatigue Severity Scale—MS Impact Scale—Pittsburgh Sleep Quality Index—MS Neuropsychological Screening Randomize Questionnaire N ? 200—Beck De

  45. Slide 45: Agitation in Alzheimer's Disease: The Potential Commercial Opportunity

    [Graphic Appears Here] Behavioral Disturbances of Neurological Disease Agitation in Alzheimer’s Disease: The Potential Commercial Opportunity

  46. Slide 46: Potential Breakthrough for Agitation in Alzheimer's Disease

    A Potential Breakthrough for Agitation in Alzheimer’s Disease Agitation is major issue for physicians and caregivers n High disease morbidity AND n main reason for institutionalization n n Significant societal AND n economic burden n No FDA approved therapies; n limited development pipeline Market r

  47. Slide 47: DM Has Potential to Offer Unique Solution for Patients

    DM Has Potential to Offer Unique Solution for Patients [Graphic Appears Here] Leverages Avanir’s presence in nursing homes and neurology/psych practices 47

  48. Slide 48: Agitation in AD Commercial Opportunity (U.S.)

    Agitation in AD Commercial Opportunity (U.S.) [Graphic Appears Here] 1% = $115 million * ~80% of nursing home residents with dementia have agitation Sources: 2012 Alzheimer’s Disease Facts & Figures (Alzheimer’s Assoc.); Alzheimer’s Dement. 2011 Jan; 7(1):80-93; USPSTF, Screening for Dementia in Pri

  49. Slide 49: Agitation in Alzheimer's Disease Scientific Rationale

    Agitation in Alzheimer’s Disease Scientific Rationale 49

  50. Slide 50: Agitation in AD Rationale—Pharmacology

    Agitation in AD Rationale—Pharmacology NMDA Serotonin Receptor Reuptake Antagonist Inhibitor Sigma-1 repinephrine Receptor Reuptake Agonist Inhibitor [Graphic Appears Here] 50

  51. Slide 51: Improving Agitation/Aggression in PBA Patients

    Improving Agitation/Aggression in PBA Patients NPI Agitation/Aggression in PBA Patients Treated with DM/Q [Graphic Appears Here] * P?0.05 for regression to evaluate does-related trend + STAR Analysis done of patients with agitation/aggression occurring once a week or more frequently at baseline The

  52. Slide 52: AVR-131: Phase II Trial in Agitation in Alzheimer's Disease

    Study AVR-131: Phase II Trial of AVP-923 Treatment of Symptoms of Agitation in Alzheimer’s Disease Primary Endpoint Agitation/Aggression domain of Neuropsychiatric Inventory (NPI) Secondary Endpoints MMSE ADCS-ADL ADCS-CGIC ADAS-Cog Quality of Life-AD Cornell Depression Scale Caregiver Strain Index

  53. Slide 53: Treatment Resistant MDD: The Potential Commercial Opportunity

    Treatment Resistant Major Depressive Disorder (MDD): The Potential Commercial Opportunity

  54. Slide 54: Potential New Option for Treatment Resistant MDD

    A Potential New Option for Treatment Resistant MDD Treatment resistant remains key challenge MDD Current therapies have challenges High number of non/inadequate responders Safety limitations Significant impact on patients, caregivers and society Few promising drugs in development n n PHYSICIANS will

  55. Slide 55: DM Has Potential to Offer Unique Solution for Patients

    DM Has Potential to Offer Unique Solution for Patients Development opportunity as adjuvant therapy (1st / 2nd line failure) or monotherapy in true refractory patients 55

  56. Slide 56: Treatment Resistant MDD Commercial Opportunity (U.S.)

    Treatment Resistant MDD Commercial Opportunity (U.S.) 15.7 million with Depression [Graphic Appears Here] 7 million patients in treatment 4.6 million patients refractory* to 1st line 2.3 million patients refractory* to multiple lines 1% = $165—$330 million Sources: http://nimh.nih.gov; CDC; J Affect

  57. Slide 57: Treatment Resistant MDD Scientific Rationale

    Treatment Resistant Major Depressive Disorder (MDD) Scientific Rationale

  58. Slide 58: Treatment Resistant MDD Rationale—Pharmacology

    Treatment Resistant MDD Rationale—Pharmacology NMDA Serotonin Receptor Reuptake Antagonist Inhibitor Sigma-1 repinephrine Receptor Reuptake Agonist Inhibitor 58

  59. Slide 59: Treatment Resistant MDD Rationale – Clinical

    Treatment Resistant MDD Rationale – Clinical Improved Depressive Symptoms in PBA Patients treated with DM/Q The Beck Depression Inventory-II (BDI-II) was included as a secondary efficacy endpoint in the pivotal phase 3 trial in PBA patients Major depression excluded Among patients with baseline BDI-

  60. Slide 60: Next Steps for Clinical Development in Treatment Resistant MDD

    Next Steps for Clinical Development in Treatment Resistant MDD Initiate Phase II study H2 FY2014 Target population Patients with MDD that have insufficient response to conventional antidepressants Randomized, placebo controlled AVP-786 or placebo adjunctive to other antidepressants Standard efficacy

  61. Slide 61: Other Opportunities

    AVAN IR pharmaceuticals Othe DIMVENS Opportunities,

  62. Slide 62: DM Has Promise in Many Other CNS Disorders

    DM Has Promise in Many Other CNS Disorders Mechanism of action, case reports and clinical observations provide scientific rationale for other promising development opportunities MOVEMENT DISORDERS COGNITIVE DISORDERS LID in Parkinson’s Alzheimer’s disease + other Huntington Chorea dementias Tardive

  63. Slide 63: Broad & Deep Future Potential Indications

    Broad & Deep Future Potential Indications Pain Refractory DPNP, Pain Behavioral Disruption/ PBA, Agitation in AD Emotional Liability Mood Disorders Treatment Resistant MDD Movement Disorders/Other PD-LID, Cognition 63

  64. Slide 64: AVP-825 Potential New Migraine Therapy

    AVP-825 Potential New Migraine Therapy

  65. Slide 65: New Licensed Product

    New Licensed Product [Graphic Appears Here] AVP-825 is an investigational drug-device combination product utilizing a novel Breath Powered intranasal technology to deliver a low-dose of sumatriptan powder. 65

  66. Slide 66: Transformational Nasal Technology for Treatment of Migraine

    Transformational Nasal Technology for Treatment of Migraine [Graphic Appears Here] Breath Powered technology allows ideal intranasal targeting: Powder is delivered deep in nasal cavity where absorption is optimal without post-nasal drip or delivery to lungs. Gamma-scintigraphy images from the same s

  67. Slide 67: PK Profile: AVP-825 Versus Traditional Nasal Spray

    PK Profile: AVP-825 Versus Traditional Nasal Spray [Graphic Appears Here] Time Post-Dose (hr) Sumatriptan plasma concentration-time profiles over the first 4 hours after administration of sumatriptan powder by the Breath-Powered device compared with the 20 mg nasal spray Source: Optinose Phase I dat

  68. Slide 68: AVP-825: Meaningful Efficacy and Onset of Action

    AVP-825: Meaningful Efficacy and Onset of Action Headache relief begins to separate at 15 minutes, significant by 30 minutes: Large effect size explains significance despite modest sample size * 80 RELIEF 70 HEADACHE 60 50 WITH 40 SUBJECTS 30 20 OF 10 % 0 [Graphic Appears Here] 0 10 20 30 40 50 60 7

  69. Slide 69: Limitations of Current Sumatriptan Formulations

    Limitations of Current Sumatriptan Formulations INJECTABLE ORAL NASAL SPRAY Injection site Slow onset of relief Inefficient pain/reactions Difficult for patients delivery/absorption Triptan sensations with nausea Nasal run-out/drip Nausea/vertigo 69

  70. Slide 70: The Evolution for Treatment of Migraine

    Roger Cady, MD The Evolution for Treatment of Migraine

  71. Slide 71: AVP-825 – A Potential New Migraine Opportunity

    AVP-825 – A Potential New Migraine Opportunity [Graphic Appears Here] Clinical profile may deliver on key unmet needs Large well-established market but high dissatisfaction—1% share of the triptan market is worth $50-65 million Peak revenue between $150-200 million AVP-825 is an investigational drug

  72. Slide 72: Summary

    Keith Katkin President & CEO Summary

  73. Slide 73: Avanir: A Leading Specialty BioPharma

    Avanir: A Leading Specialty BioPharma [Graphic Appears Here] [Graphic Appears Here] Broad Pipeline Four potential indications with significant market potential (Phase II data within 12 months) AVP-825 NDA Submission Q2 FY2014 AVP-786 IND Filing H2FY2014 73

  74. Slide 74: Multiple Catalysts over Next Months

    Multiple Catalysts over Next 12 Months [Graphic Appears Here]

  75. Slide 75: Avanir: A Leading Specialty BioPharma

    Avanir: A Leading Specialty BioPharma [Graphic Appears Here] [Graphic Appears Here] Broad Pipeline Four potential indications with significant market potential (Phase II data within 12 months) AVP-825 NDA Submission Q2 FY2014 AVP-786 IND Filing H2FY2014 75

  76. Slide 76: Closing Remarks

    Closing Remarks Keith Katkin President & CEO

  77. Slide 77: A Promising Future

    A Promising Future GROWING REVENUES (Gross run-rate ~ $110 million) [Graphic Appears Here] 1 APPROVED PRODUCT +1 Potential New Approved Product (CY2014) (potential in the $100s of millions) STUDIES IN 4 POTENTIAL NEW INDICATIONS (potential in the $ billions) LONGEVITY OF FRANCHISE (exclusivity to 20

  78. Slide 78: Important Information About NUEDEXTA

    Important Information About NUEDEXTA NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan conc

  79. Slide 79: Company Contact

    COMPANY CONTACT: Ian Clements, PhD IR & Corporate Communications iclements@avanir.com www.avanir.com www.nuedexta.com www.pbafacts.com [Graphic Appears Here] ©2013 Avanir Pharmaceuticals, Inc. All rights reserved. Avanir® and NUEDEXTA® are trademarks or registered trademarks of Avanir Pharmaceutical

Avanir Pharmaceuticals — Investor Day (October 2013) on 6ix